Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and β

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 4, 1999, Pages 275-282

  Turnbull, Rosalind M ^a   Meczes, Emma L ^a   Rogers, M Perenna ^a   Lock, Richard B ^b   Sullivan, Daniel M ^c   Finlay, Graeme J ^d   Baguley, Bruce C ^d   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

AMCA; Cl DACA; DACA; DNA topoisomerase II; mAMCA

Indexed keywords

AMSACRINE; AMSACRINE DERIVATIVE; CARBAMIC ACID DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); METHYL N [4' (9 ACRINIDYLAMINO) 2 METHOXYPHENYL]CARBAMATE; METHYL N [4' (9 ACRINIDYLAMINO)PHENYL]CARBAMATE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL KILLING; CELL STRAIN HL 60; CHO CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEWIS CARCINOMA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

ACRIDINES; AMSACRINE; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL CYCLE; CHO CELLS; CRICETINAE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; ISOENZYMES; MICE; SACCHAROMYCES CEREVISIAE; TUMOR CELLS, CULTURED;

EID: 0032773168     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050978     Document Type: Article

References (37)

1. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664
2. Austin CA, Marsh KL (1998) Eukaryotic DNA topoisomerase IIβ. Bioessays 20: 215
3. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, Fisher LM (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. J Biol Chem 270: 15739
4. Baguley BC, Leteurtre F, Riou J-F, Finlay GJ, Pommier Y (1997) A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Eur J Cancer 33: 272
5. Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridinyl methanesulphonanilide (AMSA) series. Eur J Cancer 10: 539
6. Cain BF, Atwell GJ, Seelye RN (1972) Potential antitumor agents. Part 12. 9-Anilinoacridines. J Med Chem 15: 611
7. Chan VTW, Ng SW, Eder JP, Schnipper LE (1993) Molecular cloning and identification of a point mutation in the topoisomerase-II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J Biol Chem 268: 2160
8. Cole SPC (1990) Patterns of cross-resistance in a multidrug- resistant small-cell lung carcinoma cell line. Cancer Chemother Pharmacol 26: 250
9. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163
10. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW (1997) The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol 39: 424
11. Denny WA, Cain BF, Atwell GJ, Hansch C, Panthananickal A, Leo A (1982) Potential antitumor agents. Part 36. Quantitative relationships between antitumor potency, toxicity and structure for the general class of 9-anilinoacridine antitumor agents. J Med Chem 25: 276
12. Dereuddre S, Delaporte C, Jacquemin-Sablon A (1997) Role of topoisomerase II-beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res 57: 4301
13. Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM (1994) Altered subcellular distribution of topoisomerase-II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 54: 756
14. Finlay GJ, Baguley BC (1989) Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 25: 271
15. Finlay GJ, Baguley BC, Snow K, Judd W (1990) Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst 82: 662
16. Finlay GJ, Holdaway KM, Baguley BC (1994) Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemother Pharmacol 34: 159
17. Finlay GJ, Marshall ES, Matthews JHL, Paull KD, Baguley BC (1993) In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401
18. Finlay GJ, Riou J-F, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32A: 708
19. Glisson B, Gupta R, Smallwood-Kentro S, Ross W (1986) Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res 46: 1934
20. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH (1995) Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707
21. Howard MT, Neece SH, Matson SW, Kreuzer KN (1994) Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc Natl Acad Sci USA 91: 12031
22. Meczes EL, Marsh KL, Fisher LM, Rogers MP, Austin CA (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human top2- beta construct allows the study of topoisomerase II-beta inhibitors in yeast. Cancer Chemother Pharmacol 39: 367
23. Mirski SE, Cole SP (1995) Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug- resistant human lung cancer cell line. Cancer Res 55: 2129
24. Moreland N, Finlay GJ, Dragunow M, Holdaway KM, Baguley BC (1997) Cellular responses to methyl N-[4-(9-acridinylamino)-2-methoxyphenyl]-carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells. Eur J Cancer 10: 1668
25. Nelson EM, Tewey KM, Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361
26. Nitiss JL (1994) Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol 34: S6
27. Nitiss J, Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85: 7501
28. Osheroff N (1986) Eukaryotic topoisomerase II. Characterization of enzyme turnover. J Biol Chem 261: 9944
29. Pommier Y (1997) DNA topoisomerase II inhibitors. In: Teicher BA (ed) Cancer therapeutics. Experimental and clinical agents, Part I cytotoxic agents. Humana Press, New Jersey, p 153
30. Rizvi NA, Ng SW, Sulivan D, Eder JP, Schipper LE, Chan VTW (1993) Identification of a point mutation in topoisomerase II (TOPII) cDNA in a mitoxantrone resistant Chinese hamster ovary (CHO) cell line. Proc Am Assoc Cancer Res 34: 333
31. Schneider E, Darkin SJ, Lawson PA, Ching L-M, Ralph RK, Baguley BC (1988) Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol 24: 1783
32. Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE, Rowe TC (1993) Topoisomerase-II activity involved in cleaving DNA into topological domains is altered in a multiple drug- resistant Chinese hamster ovary cell line. Mol Pharmacol 43: 207
33. Sullivan DM, Feldhoff PW, Lock RB, Smith NB, Pierce WM (1995) Characterization of an altered DNA topoisomerase II- alpha from a mitoxantrone resistant mammalian cell line hypersensitive to DNA crosslinking agents. Int J Oncol 7: 1383
34. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65: 635
35. Wasserman RA, Austin CA, Fisher LM, Wang JC (1993) Use of yeast in the study of anticancer drugs targeting DNA topoisomerases - expression of a functional recombinant human DNA topoisomerase-II-alpha in yeast. Cancer Res 53: 3591
36. Webb CD, Latham MD, Lock RB, Sullivan DM (1991) Attenuated topoisomerase-II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543
37. Zittoun R (1985) m-AMSA: a review of clinical data. Eur J Cancer Clin Oncol 21: 649